Insulin Sensitizing Agents held dominant position in the global polycystic ovary syndrome treatment market
Polycystic Ovary Syndrome Treatment Market
Insulin-resistant polycystic ovarian syndrome, inflammatory
polycystic ovary syndrome, hidden-cause polycystic ovary syndrome, and
pill-induced polycystic ovary syndrome are the four different kinds of the
condition.
Over the projection period, the high prevalence of
polycystic ovary syndrome is anticipated to fuel market expansion for
treatments for the condition. For example, the prevalence of polycystic ovary
syndrome in adolescents based on the Rotterdam criteria was 11.04 percent,
based on the National Institute of Health criteria it was 3.39 percent, and
based on the Androgen Excess and Polycystic Ovary Syndrome Society it was 8.03
percent, according to the study "The prevalence of polycystic ovary
syndrome in adolescents: A systematic review and meta-analysis" published
in September 2019.
Players in the worldwide
polycystic ovary syndrome treatment market can anticipate to benefit from
the launch of branded products as a direct treatment for the condition. The FDA
and EMA have not yet approved any medications to treat polycystic ovary
syndrome. As a result, drug producers are given the chance to control a large
portion of the market.
Comments
Post a Comment